135 related articles for article (PubMed ID: 11062244)
21. Disulfide trapping to localize small-molecule agonists and antagonists for a G protein-coupled receptor.
Buck E; Wells JA
Proc Natl Acad Sci U S A; 2005 Feb; 102(8):2719-24. PubMed ID: 15710877
[TBL] [Abstract][Full Text] [Related]
22. Chimeric receptors of the human C3a receptor and C5a receptor (CD88).
Crass T; Ames RS; Sarau HM; Tornetta MA; Foley JJ; Köhl J; Klos A; Bautsch W
J Biol Chem; 1999 Mar; 274(13):8367-70. PubMed ID: 10085065
[TBL] [Abstract][Full Text] [Related]
23. Site-specific disulfide capture of agonist and antagonist peptides on the C5a receptor.
Buck E; Bourne H; Wells JA
J Biol Chem; 2005 Feb; 280(6):4009-12. PubMed ID: 15550394
[TBL] [Abstract][Full Text] [Related]
24. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a.
Finch AM; Wong AK; Paczkowski NJ; Wadi SK; Craik DJ; Fairlie DP; Taylor SM
J Med Chem; 1999 Jun; 42(11):1965-74. PubMed ID: 10354404
[TBL] [Abstract][Full Text] [Related]
25. Mutation of glutamate 199 of the human C5a receptor defines a binding site for ligand distinct from the receptor N terminus.
Monk PN; Barker MD; Partridge LJ; Pease JE
J Biol Chem; 1995 Jul; 270(28):16625-9. PubMed ID: 7622471
[TBL] [Abstract][Full Text] [Related]
26. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
27. Structure-function relationships of human C5a and C5aR.
Huber-Lang MS; Sarma JV; McGuire SR; Lu KT; Padgaonkar VA; Younkin EM; Guo RF; Weber CH; Zuiderweg ER; Zetoune FS; Ward PA
J Immunol; 2003 Jun; 170(12):6115-24. PubMed ID: 12794141
[TBL] [Abstract][Full Text] [Related]
28. Third extracellular loop (EC3)-N terminus interaction is important for seven-transmembrane domain receptor function: implications for an activation microswitch region.
Rana S; Baranski TJ
J Biol Chem; 2010 Oct; 285(41):31472-83. PubMed ID: 20663868
[TBL] [Abstract][Full Text] [Related]
29. 1,25(OH)2D3 and cAMP synergistically induce complement 5a receptor messenger RNA.
Rubin J; Biskobing D; Titus L; Thornton DL; Catherwood BD; Nanes MS
Am J Med Sci; 1996 Feb; 311(2):73-9. PubMed ID: 8615377
[TBL] [Abstract][Full Text] [Related]
30. Ligand-induced phosphorylation of anaphylatoxin receptors C3aR and C5aR is mediated by "G protein-coupled receptor kinases.
Langkabel P; Zwirner J; Oppermann M
Eur J Immunol; 1999 Sep; 29(9):3035-46. PubMed ID: 10508278
[TBL] [Abstract][Full Text] [Related]
31. Contribution of the anaphylatoxin receptors, C3aR and C5aR, to the pathogenesis of pulmonary fibrosis.
Gu H; Fisher AJ; Mickler EA; Duerson F; Cummings OW; Peters-Golden M; Twigg HL; Woodruff TM; Wilkes DS; Vittal R
FASEB J; 2016 Jun; 30(6):2336-50. PubMed ID: 26956419
[TBL] [Abstract][Full Text] [Related]
32. The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding.
Scola AM; Higginbottom A; Partridge LJ; Reid RC; Woodruff T; Taylor SM; Fairlie DP; Monk PN
J Biol Chem; 2007 Feb; 282(6):3664-71. PubMed ID: 17158873
[TBL] [Abstract][Full Text] [Related]
33. Identification of ligand effector binding sites in transmembrane regions of the human G protein-coupled C3a receptor.
Sun J; Ember JA; Chao TH; Fukuoka Y; Ye RD; Hugli TE
Protein Sci; 1999 Nov; 8(11):2304-11. PubMed ID: 10595533
[TBL] [Abstract][Full Text] [Related]
34. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.
Bubeck P; Grötzinger J; Winkler M; Köhl J; Wollmer A; Klos A; Bautsch W
Eur J Biochem; 1994 Feb; 219(3):897-904. PubMed ID: 8112341
[TBL] [Abstract][Full Text] [Related]
35. Structural complexes of the agonist, inverse agonist and antagonist bound C5a receptor: insights into pharmacology and signaling.
Rana S; Sahoo AR; Majhi BK
Mol Biosyst; 2016 Apr; 12(5):1586-99. PubMed ID: 26978009
[TBL] [Abstract][Full Text] [Related]
36. Stabilization of an isolated helical capping box in solution by hydrophobic interactions: evidence from the NMR study of bioactive peptides from the C-terminus of human C5a anaphylatoxin.
Ni F; Carpenter KA; Ripoll DR; Sanderson SD; Hugli TE
Biopolymers; 1996 Jan; 38(1):31-41. PubMed ID: 8679942
[TBL] [Abstract][Full Text] [Related]
37. C5a receptor and interleukin-6 are expressed in tissue macrophages and stimulated keratinocytes but not in pulmonary and intestinal epithelial cells.
Fayyazi A; Sandau R; Duong LQ; Götze O; Radzun HJ; Schweyer S; Soruri A; Zwirner J
Am J Pathol; 1999 Feb; 154(2):495-501. PubMed ID: 10027407
[TBL] [Abstract][Full Text] [Related]
38. Expression of the anaphylatoxin C5a receptor in non-myeloid cells.
Zwirner J; Fayyazi A; Götze O
Mol Immunol; 1999; 36(13-14):877-84. PubMed ID: 10698342
[TBL] [Abstract][Full Text] [Related]
39. Species dependence for binding of small molecule agonist and antagonists to the C5a receptor on polymorphonuclear leukocytes.
Woodruff TM; Strachan AJ; Sanderson SD; Monk PN; Wong AK; Fairlie DP; Taylor SM
Inflammation; 2001 Jun; 25(3):171-7. PubMed ID: 11403208
[TBL] [Abstract][Full Text] [Related]
40. cDNA cloning and characterization of rat C5a anaphylatoxin receptor.
Akatsu H; Miwa T; Sakurada C; Fukuoka Y; Ember JA; Yamamoto T; Hugli TE; Okada H
Microbiol Immunol; 1997; 41(7):575-80. PubMed ID: 9272704
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
